摘要
目的 探讨缬沙坦和氨氯地平联合应用对高血压病 (EH)患者血小板活化状态和纤溶活性的影响。方法 69例EH患者随机分为缬沙坦组 ( 2 3例 )、氨氯地平组 ( 2 3例 )、缬沙坦 +氨氯地平组 ( 2 3例 )。疗程 12周。治疗前后测定血浆中血小板α 颗粒膜蛋白 (GMP 140 )、组织型纤溶酶原激活剂 (t PA)及其抑制物 (PAI 1)水平。结果 三组EH患者治疗后GMP 140含量、PAI 1活性均明显降低 (P <0 0 1) ,t PA活性显著升高 (P <0 0 1)。联合治疗组降低GMP 140和升高t PA的幅度高于缬沙坦组和氨氯地平组 (P <0 0 5 )。血浆GMP 140、PAI 1降低幅度和t PA升高幅度与血压变化无显著相关 (P >0 0 5 )。结论 缬沙坦、氨氯地平均能有效抑制血小板活化、改善纤溶活性 。
Objective To evaluate the effects of valsartan and amlodipine used alone or in combination on platelet activation and fibrinolytic activity in patients with essential hypertension (EH).Methods Sixty-nine cases with EH were divided randomly into three groups:valsartan (n=23,80～160 mg/d),amlodipine (n=23,5～10 mg/d),and combined treatment (n=23, valsartan 80 mg/d +amlodipine 5 mg/d).Treatment lasted for 12 weeks.The levels of platelet alpha-granule membrane protein (GMP-140),tissue-type plasminogen activator (t-PA) and its inhibitor (PAI-1) were measured before and after treatment.Results Levels of GMP-140 and PAI-1 activity were decreased (P<0.01),but t-PA activity was increased (P<0.01) after treatment in all the three groups. Magnitude of change of GMP-140 and t-PA in the combined treatment group was higher than that either in valsartan or in amlodipine group (P<0.05).No significant correlation between the magnitude of decrease or increase of GMP-140,PAI-1 and t-PA activity and that of blood pressures (BP) was found among all the three groups(P>0.05 ).Conclusion These findings indicate that valsartan combined with amlodipine treatment has additive effect on inhibiting platelet activation and improving fibrinolytic activity in patients with EH.
出处
《中国药物与临床》
CAS
2003年第2期111-113,共3页
Chinese Remedies & Clinics
